Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

Bakhm Jan. 14 at 3:05 AM

$RANI How long do you think it will take for them to show the initial results of the phase?

0 · Reply

TheInside2028 Jan. 13 at 10:17 PM

$RANI feb 142026 13 g deadline.

0 · Reply

pc247cz Jan. 13 at 9:48 PM

$RANI what next?

0 · Reply

APRadek Jan. 13 at 9:21 PM

$RANI since today we have new institutional buyer onboard

1 · Reply

wavw Jan. 13 at 7:46 PM

$RANI don’t know who’s selling…every rise is sold out heavily

0 · Reply

Stockwalker01 Jan. 13 at 7:34 PM

$RANI This looks really good longterm, probably keep falling today. Needs more good news

0 · Reply

TheInside2028 Jan. 13 at 5:46 PM

$RANI https://pharmaphorum.com/news/rani-completes-first-trial-of-capsule-that-could-replace-injections NEWS to us: Backed by GOOGLE $GOOG "Backed by Google’s parent company Alphabet, Rani has begun clinical trials of the RaniPill, which is capable of delivering biologic drugs such as insulin and AbbVie’s Humira into the wall of the small intestine." Hasn't hit market news yet

0 · Reply

TheInside2028 Jan. 13 at 5:34 PM

$RANI The goal is to replace the current injectable form of the drug, such as Forteo, made by Eli Lilly (LLY), with the oral version RT-102. Many patients avoid treatment because they dislike the monthly or daily injections, and an oral PTH would appeal to a much wider patient base. RANI believes the global PTH TAM will reach $2.51 billion by 2026, so their RT-102 could potentially tap into a sizeable market. This is why I see $LLY buying us at $10-$12 in the near future

0 · Reply

TheInside2028 Jan. 13 at 5:32 PM

$RANI

0 · Reply

TheInside2028 Jan. 13 at 4:11 PM

$RANI Short Interest 13,886,343 shares - source: NASDAQ Short Interest Ratio 10.18 Days to Cover Short Interest % Float 18.52 % - source: NASDAQ (short interest), Capital IQ (float) keep it up

0 · Reply

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Nov 24, 2025, 4:05 PM EST - 7 weeks ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 2 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 23, 2025, 4:05 PM EDT - 2 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:01 PM EDT - 2 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 20, 2025, 2:20 PM EDT - 3 months ago

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

Oct 20, 2025, 9:42 AM EDT - 3 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Oct 17, 2025, 7:48 AM EDT - 3 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:31 AM EDT - 3 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:30 AM EDT - 3 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Jul 15, 2025, 9:00 AM EDT - 6 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 6 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

May 19, 2025, 8:00 AM EDT - 8 months ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 8 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Mar 31, 2025, 7:15 PM EDT - 10 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 10 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Mar 20, 2024, 7:05 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 8, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 24, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 10, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 5, 2023, 5:33 PM EDT - 2 years ago

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

Bakhm Jan. 14 at 3:05 AM

$RANI How long do you think it will take for them to show the initial results of the phase?

0 · Reply

TheInside2028 Jan. 13 at 10:17 PM

$RANI feb 142026 13 g deadline.

0 · Reply

pc247cz Jan. 13 at 9:48 PM

$RANI what next?

0 · Reply

APRadek Jan. 13 at 9:21 PM

$RANI since today we have new institutional buyer onboard

1 · Reply

wavw Jan. 13 at 7:46 PM

$RANI don’t know who’s selling…every rise is sold out heavily

0 · Reply

Stockwalker01 Jan. 13 at 7:34 PM

$RANI This looks really good longterm, probably keep falling today. Needs more good news

0 · Reply

TheInside2028 Jan. 13 at 5:46 PM

0 · Reply

TheInside2028 Jan. 13 at 5:34 PM

0 · Reply

TheInside2028 Jan. 13 at 5:32 PM

$RANI

0 · Reply

TheInside2028 Jan. 13 at 4:11 PM

$RANI Short Interest 13,886,343 shares - source: NASDAQ Short Interest Ratio 10.18 Days to Cover Short Interest % Float 18.52 % - source: NASDAQ (short interest), Capital IQ (float) keep it up

0 · Reply

TheInside2028 Jan. 13 at 10:53 AM

$RANI A darkpool is increasing the short daily volume like a fool. Trying to keep it down. Cant be open put interest. Its a fool playing with fire. Need our friends over at $GME to see and join us in the squeeze Short Volume Ratio 2026-01-12 780,913 + 1,440 = 782,353 / 1,507,037 = 51.91 2026-01-09 335,661 + 1,184 = 336,845 / 557,726 = 60.40 2026-01-08 446,724 + 278 = 447,002 / 786,178 = 56.86 2026-01-07 337,629 + 3,666 = 341,295 / 782,375 = 43.62 2026-01-06 334,882 + 2,400 = 337,282 / 694,691 = 48.55 2026-01-05 588,471 + 6,353 = 594,824 / 1,058,211 = 56.21 2026-01-02 429,106 + 4,895 = 434,001 / 795,663 = 54.55 2025-12-31 460,934 + 5,269 = 466,203 / 813,104 = 57.34 2025-12-30 402,071 + 4,280 = 406,351 / 818,607 = 49.64 2025-12-29 511,455 + 2,523 = 513,978 / 1,037,303 = 49.55

0 · Reply

TheInside2028 Jan. 13 at 10:44 AM

$RANI e average one-year price target for Rani Therapeutics Holdings, Inc. is $9.44. The forecasts range from a low of $7.07 to a high of $11.55. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations. Update Frequency: Monthly

1 · Reply

Thelonius_Stonk Jan. 12 at 11:30 PM

$RANI 🤔

2 · Reply

PiviotPointMooncake Jan. 12 at 10:56 PM

$RANI the weekly is fire should climb well here and news would send it hard

0 · Reply

llchen1204 Jan. 12 at 8:40 PM

$RANI MACD in daily chart turned to green after 2 months of red

0 · Reply

TheInside2028 Jan. 12 at 8:04 PM

$RANI the PSAR has finally reversed on the daily-weekly prepping for a monster run. Sit back and do nothing or load it like we have for the last two months-manipulation at its best. 11.07 days to cover! OUCH

0 · Reply

Fishbonee Jan. 12 at 5:04 PM

$RANI 📈

0 · Reply

TheInside2028 Jan. 12 at 1:21 PM

$RANI Short Interest 12,827,731 shares - source: NASDAQ Short Interest Ratio 11.08 Days to Cover Short Interest % Float 17.11 % - source: NASDAQ (short interest), Capital IQ (float) We are gonna squeeze-lets get it out there! This thing is a pressure cooker-open interest on calls and short volume is gonna make this double without a doubt

0 · Reply

llchen1204 Jan. 12 at 4:08 AM

$RANI convention this week

1 · Reply

wavw Jan. 12 at 12:50 AM

$RANI apart from progen and chugai , they need another deal. I believe no other catalyst to move further.

0 · Reply

lisaparsons Jan. 11 at 4:20 PM

$RANI beautiful souls, can you tell me if we are nasdaq compliant. does anyone believe we will have to do a reverse split?

2 · Reply

BinaryLogic Jan. 10 at 9:12 PM

$COCH [Stochastics] Double bottom at/around $0.65, ATL as the Company continues to quietly secure intellectual property and continues its progression on Acclaim study. $16M placement in October, $1.33 strike price not yet reflected in financials. Non-compliance issue with Nasdaq requires resolution. Debt has been eliminated entirely, $20M Cash (appx) against $(15)M Total Liabilities, which equates to a Cash runway of appx 12-15mos. The Company needs a partner agreement (IMO) similar to $RANI. If/where that is secured and the Company regains compliance, multiplier upside (IMO) from this level. Start/Build/Add at $0.65 support line which might see a triple bottom retest. 100% upside to Oct-2025 placement alone.

1 · Reply

Market Cap	181.05M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,914.56%
Debt to Equity Ratio	-1.88

Volume	1,404,800
Avg Vol	5,183,860
Day's Range	N/A - N/A
Shares Out	121.51M
Stochastic %K	53%
Beta	0.42
Analysts	Strong Sell
Price Target	$9.25